TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

• Published in: Breast cancer research : BCR Vol. 22; no. 1; p. 22
• Main Authors: Vaklavas, Christos, Roberts, Brian S, Varley, Katherine E, Lin, Nancy U, Liu, Minetta C, Rugo, Hope S, Puhalla, Shannon, Nanda, Rita, Storniolo, Anna Maria, Carey, Lisa A, Saleh, Mansoor N, Li, Yufeng, Delossantos, Jennifer F, Grizzle, William E, LoBuglio, Albert F, Myers, Richard M, Forero-Torres, Andres
• Format: Journal Article
• Language: English
• Published: England BioMed Central 18.02.2020; BMC
• Subjects: Angiogenesis; Antitumor activity; Bevacizumab; Biopsy; Blood; Breast cancer; Cancer therapies; Consent; Disease; Endocrine therapy; ErbB-2 protein; Estrogens; Headache; Hormone receptor-positive breast cancer; Hypotheses; Immunotherapy; Letrozole; Luminal breast cancer; Lymphatic system; Magnetic resonance imaging; Mammography; Medical research; Monoclonal antibodies; Patients; Post-menopause; Preoperative therapy; Progesterone; Proteinuria; Remission; Ribonucleic acid; RNA; Surgery; Targeted cancer therapy; Toxicity; Tumors; Ultrasonic imaging; Urine; Vascular endothelial growth factor; Womens health; United States > US; Postmenopausal; Preoperative therapy; Hormone receptor-positive breast cancer; Breast cancer; Letrozole; Bevacizumab; Luminal breast cancer
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-020-01258-x

In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and downstaging rate. Seventy-five patients were randomized (Let/Bev n = 50, Let n = 25). Of the 45 patients evaluable for pathological response in the Let/Bev arm, 5 (11%; 95% CI, 3.7-24.1%) achieved pCR and 4 (9%; 95% CI, 2.5-21.2%) had microscopic residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0-14.2%). The rates of downstaging were 44.4% (95% CI, 29.6-60.0%) and 37.5% (95% CI, 18.8-59.4%) in the Let/Bev and Let arms, respectively. Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3 and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and confirmed on an independent cohort. In the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%; no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy. This trial is registered with ClinicalTrials.gov (Identifier: NCT00161291), first posted on September 12, 2005, and is completed.